A Phase 3 interventional study of Vortioxetine and Duloxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-18.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 3rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 611 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2008, is one of 16 in phase 3, and was the 1st registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine.
The study enrolled 611 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 12 weeks. Participants made 8 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has 1 or more the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
Drug: Vortioxetine
Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
Drug: Vortioxetine
Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
Drug: Duloxetine
Placebo-matching capsules, orally, once daily for up to 9 weeks.
Drug: Placebo
Encapsulated vortioxetine immediate-release tablets
Also known as: Lu AA21004, Brintellix®
Duloxetine capsules
Also known as: Cymbalta®
Placebo-matching capsules
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.
Time frame: Baseline and Week 8
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, and 6
Percentage of Responders in HAM-D 24 Total Score by Study Visit
A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.
Percentage of Participants With a Sustained Response in HAM-D24
A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.
Time frame: Baseline to Week 8
Percentage of Participants in MADRS Remission at Week 8
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
Time frame: Week 8
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8
Clinical Global Impression Scale-Global Improvement Scale
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.
Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 4 and 8
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.
Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
Time frame: Baseline and Week 8
Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Time frame: Baseline and Week 8
Participants took part in the study at 47 investigative sites in the United States from 10 April 2008 to 30 December 2008.
| Milestone | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Started | 153 | 153 | 153 | 152 |
| Treated | 151 | 149 | 153 | 150 |
| Completed | 120 | 99 | 122 | 110 |
| Not completed | 33 | 54 | 31 | 42 |
| Withdrew: Adverse event | 7 | 7 | 12 | 17 |
| Withdrew: Lack of efficacy | 1 | 2 | 2 | 0 |
| Withdrew: Noncompliance with study drug | 3 | 4 | 0 | 2 |
| Withdrew: Protocol deviations | 5 | 7 | 2 | 5 |
| Withdrew: Withdrawal of consent | 6 | 12 | 5 | 6 |
| Withdrew: Lost to follow-up | 8 | 19 | 8 | 11 |
| Withdrew: Reason not specified | 3 | 3 | 2 | 1 |
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8 | -10.50 ± 0.757 | -12.04 ± 0.744 | -11.08 ± 0.737 | -13.47 ± 0.750 |
The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 150, 147) | -5.12 ± 0.515 | -5.44 ± 0.497 | -5.28 ± 0.491 | -5.66 ± 0.500 |
| Week 2 (n=149, 146, 153, 149) | -7.19 ± 0.567 | -7.95 ± 0.557 | -7.99 ± 0.552 | -8.42 ± 0.562 |
| Week 4 (n=149, 146, 153, 149) | -9.39 ± 0.663 | -9.94 ± 0.651 | -8.96 ± 0.645 | -10.88 ± 0.657 |
| Week 6 (n=149, 146, 153, 149) | -10.43 ± 0.706 | -11.21 ± 0.694 | -10.97 ± 0.687 | -12.78 ± 0.700 |
A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 150, 147) | 9.2 | 8.4 | 8.7 | 10.2 |
| Week 2 (n=149, 146, 153, 149) | 15.4 | 17.1 | 17.6 | 22.1 |
| Week 4 (n=149, 146, 153, 149) | 26.2 | 30.8 | 24.2 | 34.9 |
| Week 6 (n=149, 146, 153, 149) | 32.9 | 37.7 | 37.3 | 47.0 |
| Week 8 (n=149, 146, 153, 149) | 32.2 | 41.1 | 37.9 | 51.0 |
A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Percentage of Participants With a Sustained Response in HAM-D24 | 12.1 | 15.8 | 17.0 | 21.5 |
Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Percentage of Participants in MADRS Remission at Week 8 | 22.8 | 28.8 | 23.5 | 37.6 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 150, 147) | -4.90 ± 0.530 | -5.16 ± 0.511 | -5.06 ± 0.505 | -5.49 ± 0.514 |
| Week 2 (n=149, 146, 153, 149) | -7.57 ± 0.615 | -7.71 ± 0.605 | -7.81 ± 0.599 | -8.95 ± 0.609 |
| Week 4 (n=149, 146, 153, 149) | -9.66 ± 0.693 | -9.58 ± 0.681 | -9.35 ± 0.675 | -11.34 ± 0.686 |
| Week 6 (n=149, 146, 153, 149) | -11.04 ± 0.770 | -11.25 ± 0.757 | -11.27 ± 0.750 | -13.29 ± 0.763 |
| Week 8 (149, 146, 153, 149) | -11.22 ± 0.819 | -11.61 ± 0.805 | -11.30 ± 0.797 | -14.10 ± 0.811 |
The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 149, 147) | 3.54 ± 0.067 | 3.42 ± 0.065 | 3.46 ± 0.064 | 3.31 ± 0.065 |
| Week 2 (n=149, 146, 153, 149) | 3.21 ± 0.077 | 3.17 ± 0.076 | 3.10 ± 0.075 | 2.99 ± 0.076 |
| Week 4 (149, 146, 153, 149) | 2.97 ± 0.085 | 2.93 ± 0.084 | 2.87 ± 0.083 | 2.73 ± 0.084 |
| Week 6 (149, 146, 153, 149) | 2.83 ± 0.091 | 2.82 ± 0.090 | 2.74 ± 0.089 | 2.50 ± 0.090 |
| Week 8 (n=149, 146, 153, 149) | 2.79 ± 0.098 | 2.73 ± 0.096 | 2.63 ± 0.095 | 2.39 ± 0.097 |
The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=141, 142, 149, 146) | -2.51 ± 0.310 | -2.43 ± 0.299 | -2.74 ± 0.295 | -2.88 ± 0.299 |
| Week 4 (148, 145, 152, 149) | -4.02 ± 0.348 | -3.65 ± 0.342 | -3.69 ± 0.338 | -4.89 ± 0.342 |
| Week 8 (n=148, 145, 152, 149) | -4.25 ± 0.370 | -3.98 ± 0.364 | -4.04 ± 0.360 | -5.70 ± 0.364 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 150, 147) | -2.63 ± 0.356 | -2.98 ± 0.343 | -2.55 ± 0.339 | -2.30 ± 0.346 |
| Week 2 (n=149, 146, 153, 149) | -3.82 ± 0.419 | -4.41 ± 0.412 | -3.76 ± 0.408 | -3.94 ± 0.415 |
| Week 4 (n=149, 146, 153, 149) | -5.12 ± 0.457 | -5.10 ± 0.450 | -4.25 ± 0.445 | -4.88 ± 0.454 |
| Week 6 (n=149, 146, 153, 149) | -5.84 ± 0.482 | -5.77 ± 0.474 | -4.89 ± 0.469 | -6.15 ± 0.478 |
| Week 8 (n=149, 146, 153, 149) | -5.75 ± 0.502 | -5.91 ± 0.494 | -5.29 ± 0.488 | -6.56 ± 0.498 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Week 1 (n=142, 143, 150, 147) | -0.28 ± 0.055 | -0.40 ± 0.053 | -0.37 ± 0.053 | -0.44 ± 0.054 |
| Week 2 (n=149, 146, 153, 149) | -0.63 ± 0.071 | -0.65 ± 0.069 | -0.66 ± 0.069 | -0.75 ± 0.070 |
| Week 4 (n=149, 146, 153, 149) | -0.92 ± 0.086 | -0.92 ± 0.085 | -0.90 ± 0.084 | -1.12 ± 0.085 |
| Week 6 (n=149, 146, 153, 149) | -1.11 ± 0.094 | -1.08 ± 0.092 | -1.08 ± 0.091 | -1.39 ± 0.093 |
| Week 8 (n=149, 146, 153, 149) | -1.14 ± 0.103 | -1.21 ± 0.102 | -1.17 ± 0.101 | -1.56 ± 0.102 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8 | -6.83 ± 0.638 | -6.46 ± 0.640 | -6.59 ± 0.641 | -8.91 ± 0.672 |
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
| participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Baseline: Any resource use | 40 | 51 | 42 | 42 |
| Baseline: Any hospitalization-related services | 4 | 1 | 0 | 3 |
| Baseline: Hospitalization related to depression | 2 | 1 | 0 | 0 |
| Baseline: Any sick leave | 18 | 11 | 11 | 14 |
| Baseline: Sick leave related to depression | 13 | 9 | 10 | 11 |
| Week 8: Any resource use | 21 | 19 | 20 | 27 |
| Week 8: Any hospitalization-related service | 1 | 0 | 1 | 2 |
| Week 8: Hospitalization related to depression | 0 | 0 | 0 | 1 |
| Week 8: Any sick leave | 5 | 5 | 9 | 5 |
| Week 8: Sick leave related to depression | 2 | 4 | 3 | 2 |
Collected over Adverse events were collected during the 8-week treatment period and a 4-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/151 (1.3%) | 81/151 (53.6%) |
| Vortioxetine 2.5 mg | — | 0/149 (0%) | 83/149 (55.7%) |
| Vortioxetine 5 mg | — | 3/153 (2%) | 87/153 (56.9%) |
| Duloxetine 60 mg | — | 2/150 (1.3%) | 120/150 (80%) |
| Event | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/151 | 0/149 | 0/153 | 1/150 |
| Panic attackPsychiatric disorders | 0/151 | 0/149 | 0/153 | 1/150 |
| DepressionPsychiatric disorders | 1/151 | 0/149 | 0/153 | 0/150 |
| Abortion inducedSurgical and medical procedures | 1/151 | 0/149 | 0/153 | 0/150 |
| Atrial fibrillationCardiac disorders | 0/151 | 0/149 | 1/153 | 0/150 |
| Coronary artery diseaseCardiac disorders | 0/151 | 0/149 | 1/153 | 0/150 |
| Head injuryInjury, poisoning and procedural complications | 0/151 | 0/149 | 1/153 | 0/150 |
| ConvulsionNervous system disorders | 0/151 | 0/149 | 1/153 | 0/150 |
| Event | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 16/151 | 24/149 | 44/153 | 63/150 |
| Dry mouthGastrointestinal disorders | 11/151 | 16/149 | 16/153 | 40/150 |
| HeadacheNervous system disorders | 18/151 | 20/149 | 24/153 | 21/150 |
| DizzinessNervous system disorders | 7/151 | 10/149 | 9/153 | 22/150 |
| SomnolenceNervous system disorders | 6/151 | 3/149 | 9/153 | 20/150 |
| DiarrhoeaGastrointestinal disorders | 13/151 | 7/149 | 14/153 | 19/150 |
| ConstipationGastrointestinal disorders | 11/151 | 6/149 | 6/153 | 18/150 |
| FatigueGeneral disorders | 5/151 | 3/149 | 3/153 | 13/150 |
| InsomniaPsychiatric disorders | 6/151 | 6/149 | 6/153 | 11/150 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 4/151 | 4/149 | 4/153 | 11/150 |
| Age Continuous(years) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 42.6 ± 13.76 | 42.6 ± 12.85 | 43.1 ± 13.89 | 42.7 ± 14.38 | 42.7 ± 13.70 |
| Age, Customized(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| ≤55 years | 122 | 127 | 125 | 123 | 497 |
| >55 years | 31 | 26 | 28 | 29 | 114 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Female | 93 | 98 | 106 | 91 | 388 |
| Male | 60 | 55 | 47 | 61 | 223 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Caucasian (White, including Hispanic) | 121 | 112 | 108 | 111 | 452 |
| Black | 28 | 35 | 40 | 36 | 139 |
| Asian | 3 | 3 | 3 | 3 | 12 |
| American Indian or Alaska Native | 1 | 2 | 0 | 0 | 3 |
| Native Hawaiian/ Other Pacific Islander | 0 | 1 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Hispanic/Latino | 35 | 21 | 19 | 28 | 103 |
| Non-Hispanic/Non-Latino | 118 | 132 | 133 | 123 | 506 |
| Region of Enrollment(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| United States | 153 | 153 | 153 | 152 | 611 |
| Weight(kg) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 84.22 ± 20.144 | 85.08 ± 24.126 | 88.61 ± 25.779 | 87.44 ± 20.695 | 86.34 ± 22.823 |
| Height(cm) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|
| Mean | 168.98 ± 9.141 | 169.50 ± 9.385 | 167.98 ± 9.833 | 170.37 ± 9.624 | 169.21 ± 9.515 |
7 further baseline measures are reported on the registry.
The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine